Andrew Pippas, MD
Medical Oncology · Columbus, GANPI 1831262922
Payments from drug & device makers
Across 548 payments — averaging $3256.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$800K
- Astrazeneca UK Limited$213K
- AstraZeneca$140K
- AbbVie$128K
- Incyte Corporation$76K
- Beigene, Ltd.$70K
- plus $357K from 45 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$1,784,726 in reported general payments places this provider in the 85th percentile of 68 medical oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Columbus
- Vetta HiggsColumbus$1K
- Suresh RamalingamAtlanta$10.5M
- Jonathan KaufmanAtlanta$7.7M
- Samir KhleifAugusta$5.6M
- Badi El OstaDecatur$3.5M
- Nabil SabaAtlanta$2.8M
- Olumide GbolahanAtlanta$2.7M
- Bradley CarthonAtlanta$2.7M
- Amelia LangstonAtlanta$2.1M
- Ragini KudchadkarAtlanta$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.